BTIG Research Forecasts Strong Price Appreciation for Haemonetics (NYSE:HAE) Stock

Key Points

• BTIG Research raised Haemonetics’ price target to $142 from $130 and maintained a Buy rating, implying about 14.3% upside from the cited share price.
• Haemonetics beat quarterly estimates, reporting EPS of $1.35 versus $1.29 expected and revenue of $357.8 million versus $345.1 million expected; revenue grew 9.4% year over year.
• Analyst sentiment is broadly positive: MarketBeat’s consensus is “Moderate Buy” with a $111.33 target, while shares recently traded at $124.19 after reaching a 52-week high of $132.

Haemonetics (NYSE:HAE - Get Free Report) had its target price raised by research analysts at BTIG Research from $130.00 to $142.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a "buy" rating on the medical instruments supplier's stock. BTIG Research's price objective would suggest a potential upside of 14.34% from the stock's current price.

Other research analysts also recently issued reports about the stock. Citigroup boosted their price objective on shares of Haemonetics from $79.00 to $92.00 and gave the company a "neutral" rating in a research report on Friday, August 7th. Mizuho upped their price objective on shares of Haemonetics from $95.00 to $140.00 and gave the stock an "outperform" rating in a report on Friday, October 9th. Raymond James Financial raised their target price on shares of Haemonetics from $105.00 to $125.00 and gave the stock an "outperform" rating in a research report on Thursday, September 3rd. Barrington Research lifted their target price on shares of Haemonetics from $118.00 to $140.00 and gave the company an "outperform" rating in a research note on Friday, October 9th. Finally, Robert W. Baird boosted their price target on shares of Haemonetics from $96.00 to $119.00 and gave the company an "outperform" rating in a research report on Friday, August 21st. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Haemonetics currently has a consensus rating of "Moderate Buy" and a consensus price target of $111.33.

Haemonetics Trading Down 2.5%

HAE traded down $3.23 during midday trading on Thursday, reaching $124.19. 413,083 shares of the company's stock traded hands, compared to its average volume of 807,345. Haemonetics has a 52 week low of $51.00 and a 52 week high of $132.00. The company has a debt-to-equity ratio of 1.40, a current ratio of 3.08 and a quick ratio of 1.91. The firm has a fifty day moving average of $110.86 and a two-hundred day moving average of $79.55. The stock has a market capitalization of $5.65 billion, a price-to-earnings ratio of 60.16, a P/E/G ratio of 2.40 and a beta of 0.63.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.06. The firm had revenue of $357.76 million for the quarter, compared to analysts' expectations of $345.15 million. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%. The business's revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.27 earnings per share. On average, equities analysts anticipate that Haemonetics will post 5.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its holdings in shares of Haemonetics by 21.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier's stock valued at $74,731,000 after purchasing an additional 233,119 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Haemonetics by 1,191.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 453,579 shares of the medical instruments supplier's stock worth $47,762,000 after buying an additional 418,470 shares in the last quarter. Bank of America Corp DE bought a new stake in Haemonetics in the 2nd quarter worth about $33,326,000. William Blair Investment Management LLC purchased a new position in Haemonetics in the 2nd quarter worth about $24,906,000. Finally, Bank of New York Mellon Corp purchased a new position in Haemonetics in the 2nd quarter worth about $21,566,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Fiscal Q2 earnings were $1.35 per share, above the $1.29 analyst consensus and up from $1.27 a year earlier. Revenue rose 9.4% year over year to $357.8 million, topping the $345.1 million estimate. Haemonetics reports Q2 results
• Positive Sentiment: Haemonetics raised its fiscal 2027 revenue and organic-growth outlook following the quarter, signaling management sees continued growth. Haemonetics raises FY27 revenue outlook
• Neutral Sentiment: The stock recently reached a 52-week high, and its elevated valuation may heighten expectations or encourage some investors to take profits. The available reports do not establish this as the cause of the share decline. Haemonetics hits a fresh high

About Haemonetics

Haemonetics Corporation NYSE: HAE is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company's offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.